Outcomes | GAR | Events, n (%) | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
---|---|---|---|---|---|---|
Early neurological deterioration†| Q1 (n = 136) | 4 (12.5%) | Reference | Reference | ||
Q2 (n = 141) | 4 (12.5%) | 0.49 [0.28;0.86] | 0.96 | 1.08 [0.24;4.85] | 0.916 | |
Q3 (n = 139) | 7 (21.9%) | 1.72 [0.49;6.95] | 0.398 | 1.57 [0.45;7.01] | 0.454 | |
Q4 (n = 137) | 17 (53.1%) | 4.52 [1.60;16.5] | 0.003 | 4.47 [1.46;17.02] | 0.014 | |
P for trend |  < 0.001 | 0.005 | ||||
Stroke-associated pneumonia‡ | Q1 (n = 136) | 30 (14.4%) | Reference | Reference | ||
Q2 (n = 141) | 45 (21.6%) | 1.65 [0.97;2.85] | 0.067 | 1.45 [0.84;2.54] | 0.102 | |
Q3 (n = 139) | 65 (31.2%) | 3.08 [1.84;5.27] |  < 0.001 | 2.22 [1.29;3.86] | 0.002 | |
Q4 (n = 137) | 68 (32.7%) | 3.46 [2.06;5.92] |  < 0.001 | 2.32 [1.34;4.06] | 0.002 | |
P for trend |  < 0.001 | 0.244 | ||||
ICH# | Q1 (n = 136) | 12 (11.4%) | Reference | Reference | ||
Q2 (n = 141) | 31 (29.5%) | 2.88 [1.44;6.13] | 0.002 | 2.39 [1.17;5.21] | 0.020 | |
Q3 (n = 139) | 28 (26.7%) | 2.58 [1.27;5.53] | 0.008 | 1.84 [0.89;4.02] | 0.109 | |
Q4 (n = 137) | 34 (32.4%) | 3.37 [1.70;7.13] |  < 0.001 | 2.63 [1.29;5.68] | 0.010 | |
P for trend | 0.002 | 0.108 | ||||
sICH§ | Q1 (n = 136) | 3 (14.3%) | Reference | Reference | ||
Q2 (n = 141) | 9 (42.9%) | 2.92 [0.83;14.1] | 0.098 | 2.82 [0.80;13.06] | 0.131 | |
Q3 (n = 139) | 5 (23.8%) | 1.62 [0.37;8.54] | 0.522 | 1.59 [0.37;8.08] | 0.541 | |
Q4 (n = 137) | 4 (19.0%) | 1.32 [0.27;7.26] | 0.731 | 1.44 [0.30;7.60] | 0.647 | |
P for trend | 0.917 | 0.532 | ||||
Three-month poor functional outcome (mRS 3–6) ‖ | Q1 (n = 136) | 56 (17.6%) | Reference | Reference | ||
Q2 (n = 141) | 76 (23.9%) | 1.67 [1.04;2.69] | 0.035 | 1.47 [0.86;2.53] | 0.155 | |
Q3 (n = 139) | 87 (27.4%) | 2.38 [1.47;3.89] |  < 0.001 | 1.45 [0.83;2.54] | 0.190 | |
Q4 (n = 137) | 99 (31.1%) | 3.70 [2.24;6.19] |  < 0.001 | 2.06 [1.13;3.77] | 0.018 | |
P for trend |  < 0.001 | 0.013 |